-
Genetic Screening to Reduce Abacavir Hypersensitivity Reactions
Screening for the HLA B5701 allele prior to initiation of abacavir therapy may help reduce the incidence of abacavir hypersensitivity reaction.
AIDS Clinical Care, June 2006
-
Pravastatin Increased Subcutaneous Fat in HIV-Infected Men
Since a positive effect of statins on adipocytes is biologically plausible, researchers should conduct larger follow-up studies to confirm these results in more heterogeneous patient populations.
AIDS Clinical Care, June 2006
-
Concurrent Treatment of HIV and TB
New case-control results add to a growing body of evidence that supports aggressively treating both HIV and TB.
AIDS Clinical Care, May 2006
-
Does PI Use During Pregnancy Increase the Risk for Preterm Delivery?
Prospective, observational findings from a single center with a strict PI protocol suggest yes, but definitive answers must come from randomized trials.
AIDS Clinical Care, May 2006
-
Virologic Success and Resistance in Triple-Drug Regimens
Drug potency, sanctuary penetration, and high genetic barriers to resistance may all play a role in the effectiveness of boosted PI regimens.
AIDS Clinical Care, April 2006
-
Atazanavir with PPIs: Are They Always Contraindicated?
One report found that atazanavir levels were not substantially influenced by PPIs; another that virologic failure rates did not increase. Yet both studies were too small to warrant changes in current recs.
AIDS Clinical Care, April 2006
-
After M184V, Continue the 3TC
Patients with the M184V mutation who continued 3TC alone, instead of stopping all treatment, had virologic and clinical benefits, and no new resistance mutations were observed.
AIDS Clinical Care, April 2006
-
Finally, some good news about CCR5 antagonists
Though maraviroc has proven potent and well tolerated in a short-term monotherapy trial,the toxicity and efficacy of co-receptor switching and infection need to be closely monitored in future studies.
AIDS Clinical Care, March 2006
-
Pharmacokinetic factors and the discontinuation of efavirenz
This report is the first to examine the role of efavirenz-elimination pharmacokinetics and pharmacogenetics in the emergence of resistance after discontinuation of antiretrovirals.
AIDS Clinical Care, March 2006
-
A Single Pill for HIV Infection Nears Reality
Tenofovir, FTC, and efavirenz might soon be available in a single pill, a major advance considering that combination therapies once involved high burden and complex dosing schedules.
AIDS Clinical Care, February 2006
-
Drug Interactions Might Provoke Tenofovir-Associated Renal Failure
A review of 27 cases suggests that ritonavir, ddI, and atazanavir might raise the risk for tenofovir-associated renal failure.
AIDS Clinical Care, February 2006
-
Studies Disagree on Frequency of Late CNS Side Effects from Efavirenz
How common are late CNS side effects, and are elevated plasma efavirenz levels still to blame in these cases?
AIDS Clinical Care, January 2006
-
Diabetes Drugs for HIV Lipodystrophy
Rosiglitazone and metformin had differing modest effects on fat and plasma lipid parameters associated with HIV lipodystrophy.
AIDS Clinical Care, November 2005
-
An Added Value of Rapid Testing: Improved Quality of Care
In a retrospective study, rapid HIV testing in the emergency department offered several advantages over conventional testing in the inpatient setting.
AIDS Clinical Care, October 2005
-
HIV Drug Resistance in Europe
Two new studies suggest that 10% of treatment-naive patients in Europe  and 20% of treated patients in the U.K. specifically  have resistance to HIV drugs.
AIDS Clinical Care, October 2005
-
Detectable Viremia on Treatment: How Fast Does Resistance Accumulate?
In a cohort of patients with extensive treatment experience and stable CD4-cell counts, genotypic resistance emerged slowly over a median follow-up of 9 months.
AIDS Clinical Care, October 2005
-
Prevalence of Coreceptor Use in Treatment-Naive Patients
Tropism assays will likely be necessary to identify suitable candidates for CCR5 inhibitors, especially as CD4-cell counts fall.
AIDS Clinical Care, September 2005
-
Can Valproic Acid Help Deplete Latent Reservoirs of HIV?
In a proof-of-concept study, valproic acid and intensified antiretroviral therapy cleared HIV from resting CD4 cells in vivo.
AIDS Clinical Care, September 2005
-
3TC Still Active Versus 3TC-Resistant Virus
Subjects with 3TC-resistant virus stopped taking 3TC and sustained an increase in viral load.
AIDS Clinical Care, August 2005
-
More Concern About Tenofovir + ddI
Findings from a small study are consistent with a growing body of data highlighting problems with tenofovir + ddI.
AIDS Clinical Care, July 2005
-
Treatment Response at 6 Months Predicts Long-Term Outcomes
In a cohort of patients starting their first PI-based regimen, 5-year prognosis was most accurately assessed by evaluating CD4-cell count and viral load after 6 months of therapy.
AIDS Clinical Care, July 2005
-
Boosted Atazanavir versus Lopinavir in Treatment-Experienced Patients
In this large study of treatment-experienced patients, how did these boosted PIs compare?
AIDS Clinical Care, June 2005
-
FDA Approval: Tipranavir
This new agent offers an important new option for salvage therapy in treatment-experienced patients, particularly those who have viruses harboring multiple PI-resistance mutations.
AIDS Clinical Care, June 2005
-
New Guidelines on Treating Chronic Hepatitis B and C in HIV-Coinfected Patients
The statement complements previous guidelines for treating HBV and HCV monoinfection and for treating opportunistic infections (including viral hepatitis) in HIV-infected patients.
AIDS Clinical Care, June 2005
-
Undetectable Viral Load Without Treatment: Not as Rare as Previously Thought
The results of the present study highlight the hazards of overestimating the benefits of treating acute infection based on uncontrolled observations.
AIDS Clinical Care, May 2005
